After targeted sequencing for clinically actionable driver mutations, the most common identified were NF2 and POLE. A total of 13 primary or recurrent specimens (34%) were NF2 mutation positive, which is consistent with prior genetic investigations that have cited sporadic NF2 mutations in up to half of studied meningiomas [16, 17, 20]. The gene discussed is NF2; the disease is meningioma.